Mycosis Fungoides is typically an indolent disease in early stages. However,
approximately 30% of patients have advanced staged disease at presentation and 20%
will develop it at some time. These patients have a poorer prognosis with a median
survival of 2-4 years. The only curative option for mycosis fungoides may be
hematopoietic allogeneic stem cell transplantation. We report the case of a patient
with mycosis fungoides in an advanced stage (IIB), refractory to treatment options.
She underwent allogeneic hematopoietic stem-cell transplantation (allo-HSCT). The
patient remains in complete remission nineteen months after allo-HSCT. Allogeneic
transplantation can alter the natural history of mycosis fungoides and should be
considered in patients who have refractory disease or short-lived responses with
standard therapies.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.